Combining GHR antagonism with life extending compounds: a search for synergies

Ohio University’s Heritage College of Osteopathic Medicine, earned a $3.1 million NIH-funded grant to investigate whether antagonizing the growth hormone receptor (GHR) in combination with promising life-extending compounds can synergistically improve health during aging and extend lifespan. Previous evidence indicates that reduced growth hormone action is associated with slowed aging, the project aims to test combinations of interventions rather than single therapies, pursuing a translational path from molecular mechanisms to whole-animal outcomes with the goal of identifying approaches that could ultimately enhance healthspan in older adults.

The 10-year funding, seeks to determine whether combined treatments produce additive or synergistic benefits for tissue maintenance, metabolic health and resistance to age-associated decline. The rationale for this combinatorial approach reflects a broader recognition in aging biology that multiple pathways contribute to organismal aging and that targeting complementary mechanisms simultaneously may produce greater benefit than modulating single pathways alone.

Over its multi-year course, the GHR combination study will evaluate safety, efficacy and mechanistic endpoints relevant to muscle performance, metabolic function, pain and functional independence in aging models, with the objective of identifying candidate combination therapies that merit further preclinical development and potential clinical translation. Importantly, the program emphasizes rigorous, hypothesis-driven testing of interactions between growth hormone antagonism and established or emerging life-extending compounds, with the long-term ambition of informing interventions that improve health outcomes and increase healthy lifespan for aging populations.